Senior Director, Consumer Scientific Innovation, Johnson & Johnson Innovation
Stacy is passionate about accelerating innovation and entrepreneurship in the consumer health ecosystem. For nearly two decades, Stacy has been a leader in translating innovative science into transformative commercial solutions for the health consumer. Her experience includes venture capital investing, intellectual property licensing and strategic partnering, and business strategy and incubation, with deep experience and insights across the life sciences, healthcare, diagnostics, digital health, nutrition and consumer product industries, particularly where such markets are converging and ripe for disruption. In 2014, Stacy joined Johnson & Johnson Innovation as Senior Director of Consumer Scientific Innovation. In this role, Stacy leads efforts to establish a high-value innovation portfolio for Johnson & Johnson’s Consumer Companies. Additionally, Stacy currently serves an advisor to the Springboard Enterprises Life Sciences Council and the UCSF Clinical and Translational Research Institute T1 Catalyst Program.
Prior to joining Johnson & Johnson, Stacy was a partner at Physic Ventures, a venture capital firm investing in technology-enabled solutions that empower consumers to improve their health and wellbeing, where she led investment activities in personalized health and diagnostics, including an investment in T2 Biosystems (NASDAQ: TTOO). Stacy has been actively involved in the design and execution of science-enabled innovation strategies, business incubation opportunities, and advising senior management of global CPG enterprises and early stage companies in the personalized health and medical technology sectors. Previously, Stacy held leadership positions in the business development groups at Genentech and Third Wave Technologies and was a technology transactions attorney at Wilson, Sonsini, Goodrich & Rosati. Stacy earned her B.A. in Sociology from the University of Pennsylvania, and received her J.D. from Vanderbilt Law School.
In this panel discussion, prominent healthcare investors from pharmaceutical companies, venture capital firms, incubators, and funding agencies, will share their visions on what’s next in innovative healthcare technologies, and their investment strategies to capture such opportunities.